Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
This clinical trial update notes that IASO104 is being evaluated in an early-phase 1 study for relapsed/refractory multiple myeloma and plas…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The CHAAMP internal pilot study is currently recruiting. It targets multiple myeloma and related plasma cell disorders, including MGUS and s…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma [NA]
An application study evaluating 68Ga-NOTA-BCMA nanoantibody imaging for multiple myeloma is described; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological Cancer [NA]
Clinical trial update indicating termination of a study assessing a sensory rehabilitation program for olfactory and gustatory alterations i…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma [NA]
This clinical trial investigates whether adding controlled breathing to therapeutic exercise benefits people with multiple myeloma. The stud…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update describing a Phase 1/2 study evaluating the combination of talquetamab and teclistamab in relapsed or refractory mul…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study [EARLY_Phase 1]
Early-phase 1 pilot study investigating PET imaging of cancer patients with the radiopharmaceutical 124I-PUH71, with the trial status curren…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
This document updates the status of a clinical trial evaluating Selinexor (Nexpovio) in relapsed or refractory multiple myeloma, indicating …
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1]
An early-phase study evaluating sotatercept (ACE-011) in combination with lenalidomide or pomalidomide and dexamethasone for relapsed/refrac…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating isatuximab in combination with belantamab mafodotin, pomalidomide, and dexamethasone for relapsed/refractory multip…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype [Phase 1]
A Phase 1 trial evaluating dose modifications of systemic anti-cancer therapy in individuals with the Duffy null phenotype. The study enroll…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial update indicates that JY232 injection is being studied for relapsed/refractory multiple myeloma and …
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating naive HBI0101 CAR-T therapy in relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease [Phase 2]
Phase 2 clinical trial evaluating a triple combination of mezigdomide, carfilzomib, and dexamethasone for relapsed or refractory multiple my…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Moving Foward With Myeloma (MFM) [NA]
The update indicates plans to move forward with a multiple myeloma trial led by the Medical College of Wisconsin, which is not yet recruitin…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments [Phase 2]
A Phase 2 clinical trial in multiple myeloma is evaluating sequential therapy guided by minimal residual disease (MRD) assessments. The stud…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD) [NA]
A clinical trial updating on the mechanisms of clonal and non-clonal cytopenia after CAR-T cell therapy in patients with multiple myeloma or…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: A Study of NINLARO® in Chinese Adults With Multiple Myeloma
This clinical trial update reports the status of a study evaluating NINLARO (ixazomib) in Chinese adults with multiple myeloma; the trial is…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse [Phase 2]
This Phase 2 clinical trial update examines linvoseltamab plus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma to de…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial evaluating palifermin in combination with leuprolide acetate to promote immune recovery after total body irradiation-…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: IASO206 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial of IASO206 for relapsed/refractory multiple myeloma is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial at Mayo Clinic evaluating low-dose selinexor in combination with choline salicylate for relapsed or refractory Hodgkin lymph…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma. [Phase 2, Phase 3]
A multicenter prospective diagnostic study is evaluating 68Ga-BCMA PET/CT to target BCMA expression in multiple myeloma. The Phase 2/3 trial…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma [Phase 4]
A Phase 4 clinical trial is evaluating whether adding low-dose lenalidomide to ixazomib maintenance improves outcomes for high-risk multiple…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1b study is evaluating talquetamab bridging therapy followed by cilta-cel in relapsed/refractory multiple myeloma; the trial is curr…